C4 Therapeutics, Inc.

Nasdaq:CCCC

Biological Products, (No Diagnostic Substances)·WATERTOWN, MA

CEO

Hirsch Andrew

CFO

Adams Kendra

Financials

20 shown

Type	Period	Ended	Filed
10-K	FY 2025	12/31/25	2/26/26	→
10-Q	Q3 2025	9/30/25	11/6/25	→
10-Q	Q2 2025	6/30/25	8/7/25	→
10-Q	Q1 2025	3/31/25	5/7/25	→
10-K	FY 2024	12/31/24	2/27/25	→
10-Q	Q3 2024	9/30/24	10/31/24	→
↓

Earnings Releases (8-K)

26 shown

Filed	Period
2/26/26	Q1 FY2026	→
11/6/25	Q4 FY2025	→
8/7/25	Q3 FY2025	→
5/7/25	Q2 FY2025	→
2/27/25	Q1 FY2025	→
1/14/25	Q4 FY2025	→
↓

News (8-K)

45 shown

Filed	Type	Description
1/14/26	Reg FD	Regulation FD Disclosure	→
10/16/25	Agreement	Entry into a Material Definitive Agreement	→
10/16/25	Other	Other Events	→
10/1/25	Reg FD	Regulation FD Disclosure	→
9/22/25	Reg FD	Regulation FD Disclosure	→
6/18/25	Vote	Amendments to Articles of Incorporation or Bylaws	→
↓

Prospectuses & Registrations

26 shown

Filed	Form	Description
2/26/26	S-8	S-8	→
12/10/25	424B5	424B5	→
11/21/25	S-3	S-3	→
10/16/25	424B5	424B5	→
10/16/25	FWP	FWP	→
4/29/25	ARS	ARS	→
↓

Filing History(501 filings)

TypeDateAccessionPeriodSize

144

Mar 9, 2026

0001950047-26-002361

—

5.3 KB

S-8

Feb 26, 2026

0001628280-26-012002S-8

—

229.5 KB

10-K

Feb 26, 2026

0001628280-26-01200010-K

Dec 31, 2025

12.0 MB

8-K

Feb 26, 2026

0001628280-26-0119718-K

Feb 26, 2026

235.7 KB

Feb 18, 2026

0001470831-26-000180FORM 4

Feb 13, 2026

11.2 KB

Feb 18, 2026

0001470831-26-000179FORM 4

Feb 13, 2026

8.3 KB

Feb 18, 2026

0001470831-26-000178FORM 4

Feb 13, 2026

11.2 KB

Feb 18, 2026

0001470831-26-000177FORM 4

Feb 13, 2026

368.1 KB

Feb 18, 2026

0001470831-26-000176FORM 4

Feb 13, 2026

8.3 KB

Feb 18, 2026

0001470831-26-000175FORM 4

Feb 13, 2026

11.2 KB

Feb 18, 2026

0001470831-26-000174FORM 4

Feb 13, 2026

8.3 KB

SCHEDULE 13G/A

Feb 17, 2026

0000947871-26-000188

—

14.9 KB

SCHEDULE 13G/A

Feb 17, 2026

0000902664-26-001046

—

10.3 KB

SCHEDULE 13G/A

Feb 12, 2026

0001213900-26-015656

—

30.9 KB

SCHEDULE 13G/A

Feb 11, 2026

0000895421-26-000033

—

11.6 KB

Jan 16, 2026

0001470831-26-000045FORM 4

Jan 16, 2026

4.4 KB

8-K

Jan 14, 2026

0001628280-26-0020108-K

Jan 14, 2026

191.1 KB

Jan 5, 2026

0001470831-26-000009FORM 4

Jan 2, 2026

363.5 KB

Jan 5, 2026

0001470831-26-000008FORM 4

Jan 2, 2026

4.9 KB

EFFECT

Dec 10, 2025

9999999995-25-003638

—

1.7 KB

424B5

Dec 10, 2025

0001193125-25-314449424B5

—

379.9 KB

S-3

Nov 21, 2025

0001628280-25-053575S-3

—

26.2 MB

SCHEDULE 13G/A

Nov 14, 2025

0000947871-25-001020

—

14.8 KB

SCHEDULE 13G/A

Nov 13, 2025

0000814133-25-000117

—

6.2 KB

10-Q

Nov 6, 2025

0001628280-25-04985410-Q

Sep 30, 2025

6.4 MB

25 filings shown

Filed	Form	Description
4/29/25	DEFA14A	DEFA14A	→
4/29/25	DEF 14A	DEF 14A	→
4/16/25	PRE 14A	PRE 14A	→
4/29/24	DEFA14A	DEFA14A	→
4/29/24	DEF 14A	DEF 14A	→
4/28/23	DEFA14A	DEFA14A	→
↓

C4 Therapeutics, Inc.

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(501 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
2/18/26	4	4	→
2/18/26	4	4	→
2/18/26	4	4	→
2/18/26	4	4	→
2/18/26	4	4	→
2/18/26	4	4	→
↓

Filed	Form	Description
3/9/26	144	144	→
2/17/26	SCHEDULE 13G/A	SCHEDULE 13G/A	→
2/17/26	SCHEDULE 13G/A	SCHEDULE 13G/A	→
2/12/26	SCHEDULE 13G/A	SCHEDULE 13G/A	→
2/11/26	SCHEDULE 13G/A	SCHEDULE 13G/A	→
12/10/25	EFFECT	EFFECT	→
↓